Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A-Reference-Cited by-同舟云学术

Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A

Published:2014-01-29 Issue:4 Volume:20 Page:593-600
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Gu J-M.¹,Ramsey P.¹,Evans V.¹,Tang L.²,Apeler H.²,Leong L.¹,Murphy J. E.²,Laux V.¹,Myles T.¹

Affiliation:

1. Hematology Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA

2. Biological Research; US Innovation Center; Bayer HealthCare Pharmaceuticals; San Francisco CA USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12374/fullpdf

Reference29 articles.

1. National Hemophilia Foundation. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007

2. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

3. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue;Minno;Haemophilia,2010

4. Therapeutic antibody fragments with prolonged in vivo half-lives;Chapman;Nat Biotechnol,1999

5. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers;Ivens;Haemophilia,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis;Journal of Clinical Medicine;2024-06-30

2. Variability in combinations of APTT reagent and substrate plasma for a one‐stage clotting assay to measure factor VIII products;International Journal of Laboratory Hematology;2024-03

3. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories;Haemophilia;2023-10-30

4. Intravenous immunoglobulin treatment for obstetric antiphospholipid syndrome refractory to conventional therapy: A single-arm, open-labelled multicentre clinical trial;Modern Rheumatology;2023-06-21

5. Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies;Research and Practice in Thrombosis and Haemostasis;2023-02